Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer

Journal of Immunotherapy

Volumn 37, Issue 4, 2014, Pages 250-255

  Shi, Sheng Bin ^a   Tang, Xiao Yong ^a   Tian, Jing ^a   Chang, Chun Xiao ^a   Li, Pei ^a   Qi, Jie Lin ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Cytokine induced killer cells; Dendritic cells; Erlotinib; Maintenance therapy; NSCLC

Indexed keywords

ERLOTINIB; PLATINUM; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; IMMUNOLOGICAL TOLERANCE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADOPTIVE IMMUNOTHERAPY; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RISK FACTOR; TRANSPLANTATION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84898008655     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000015     Document Type: Article

References (39)

1. Ramalingam S, Belani CP. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13(suppl 1):5-13.
2. Azzoli CG, Baker S Jr, Temin S. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract. 2010;6:39-43.
3. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol. 2009;20(suppl 4):68-70.
4. Lima JP, dos Santos LV, Sasse EC, et al. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. Eur J Cancer. 2009;45:601-607.
5. Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol. 2007;25:5233-5239.
6. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001;19:1336-1343.
7. Socinski MA, Stinchcombe TE. Duration of first-line chemotherapy in advanced non-small-cell lung cancer: less is more in the era of effective subsequent therapies. J Clin Oncol. 2001;25:5155-5157.
8. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18: 2095-2103.
9. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354-2362.
10. Hensing TA, Schell MJ, Lee JH, et al. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005;47:253-259.
11. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003;21:2933-2939.
12. Brodowicz T, Krzakowski M, Zwitter M, et al. Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small-cell lung cancer: a phase III trial. Lung Cancer. 2006; 52:155-163.
13. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced nonsmall- cell lung cancer. J Clin Oncol. 2009;27:591-598.
14. Sekine I, Nokihara H, Sumi M, et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Thorac Oncol. 2006;1:810-815.
15. Muir VJ, Dhillon S. Erlotinib: as maintenance monotherapy in non-small-cell lung cancer. BioDrugs. 2011;25:139-146.
16. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521-529.
17. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006;311: 1780-1784.
18. Gunzer M, Jä nich S, Varga G, et al. Dendritic cells and tumor immunity. Semin Immunol. 2001;13:291-302.
19. Baxevanis CN, Gritzapis AD, Tsitsilonis OE, et al. HER-2/ neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int J Cancer. 2002;98:864-872.
20. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 2002;63:1727-1733.
21. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebocontrolled phase 3 study. Lancet Oncol. 2010;11:521-529.
22. Walleser S, Ray J, Bischoff H, et al. Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. Clinicoecon Outcomes Res. 2012;4:269-275.
23. Zoll B, Lefterova P, Ebert O, et al. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL- 12 in vitro stimulation. Cytokine. 2000;12:1385-1390.
24. Yang XJ, Huang JA, Lei W, et al. Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on lung cancer in vitro and in vivo. Ai Zheng. 2006;25:1329-1333.
25. Zhang S, Zhang SQ, Bai CX. The anti-tumor effects of dendritic cells co-cultured with cytokine-induced killer cells after chemotherapy. Zhonghua Jie He He Hu Xi Za Zhi. 2004;27:315-319.
26. Shi SB, Ma TH, Li CH, et al. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori. 2012;98: 314-319.
27. Zhong R, Teng J, Han B. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011;60:1497-1502.
28. Wu C, Jiang J, Shi L, et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 2008;28(6B):3997-4002.
29. Zhao G, Huang Y, Ye L, et al. Therapeutic efficacy of traditional vein chemotherapy and bronchial arterial infusion combining with CIKs on III stage non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2009;12:1000-1004.
30. Li H, Wang C, Yu J, et al. Dendritic cell-activated cytokineinduced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy. 2009;11:1076-1083.
31. Guermonprez P, Valladeau J, Zitvogel L, et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621-667.
32. Troy AJ, Summers KL, Davidson PJ, et al. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res. 1998;4:585-593.
33. Dauer M, Lam V, Arnold H, et al. Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. J Immunol Methods. 2008;337:97-105.
34. Um SJ, Choi YJ, Shin HJ, et al. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung Cancer. 2010;70:188-194.
35. Babatz J, Röllig C, Löbel B, et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother. 2006;55:268-276.
36. Zhuang X, Xia X, Wang C, et al. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol. 2010;18:24-28.
37. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94: 275-280.
38. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14:5220-5227.
39. Shao L, Song Z, Hu L, et al. Analysis of the efficacy and survival of third-line treatment in advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2012;15:369-374.